ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Engineered Peptide Self-Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
STING agonists (e.g., cGAMP), which function as immunotherapeutic agents activating the stimulator of interferon genes (STING) pathway, hold promise for treating pediatric solid tumors including neuroblastoma. However, their clinical translation is hindered by limitations including burst release, short half-life, poor targeting, and low intracellular delivery efficiency. In this study, we engineered a peptide self-assembled nanofiber (NFSA) based on the specific interaction mechanism between STING protein and cGAMP. By hydrophobically modifying the cGAMP-binding amino acid sequences on STING, two amphiphilic peptides, MP1 and MP2, were obtained, which self-assembled into nanofibers to efficiently encapsulate cGAMP. The NFSA showed excellent biocompatibility and low toxicity both in vitro and in vivo. It enabled pH-responsive cGAMP release, promoted cellular uptake, enhanced the endoplasmic reticulum (ER) localization, and activated the STING pathway. NFSA also promoted dendritic cell maturation and shifted tumor-associated macrophages to the anti-tumor M1 type. In vivo, NFSA reduced neuroblastoma growth, increased CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.